
-
Daré Bioscience, Inc. NasdaqCM:DARE Daré Bioscience, Inc., a biopharmaceutical company, develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of dyspareunia or pain during sexual intercourse; and DARE-HPV, a fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert for the treatment of cervical intraepithelial neoplasia and other human papillomavirus related pathologies. In addition, the company develops DARE-PDM1, a hydrogel formulation of diclofenac for vaginal administration to treat primary dysmenorrhea; DARE-204 and DARE-214, injectable formulations of etonogestrel that provides contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. Further, it develops DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design controlled contraceptive option; DARE-RH1, an approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein; DARE-LBT, a hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; and DARE-GML, a multi-target antimicrobial agent. Daré Bioscience, Inc. is headquartered in San Diego, California.
Location: 3655 Nobel Drive, San Diego, CA, 92122, United States | Website: https://darebioscience.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
18.73M
Cash
10.33M
Avg Qtr Burn
N/A
Short % of Float
0.70%
Insider Ownership
1.57%
Institutional Own.
9.40%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
XACIATO (DARE-BV1) Details Bacterial infection | Approved Quarterly sales | |
Ovaprene® Details Contraceptive | Phase 3 Data readout | |
Sildenafil Cream, 3.6% Details Sexual dysfunction, Sexual desire disorder | Phase 3 Initiation | |
DARE-VVA1 (Tamoxifen formulation) Details Vulvovaginal Candidiasis | Phase 2 Initiation | |
DARE-PDM1 Details Primary dysmenorrhea | Phase 1 Update | |
DARE-PTB1 Details Preterm birth | Phase 1 Initiation | |
DARE-HRT1 Details Menopause | IND Submission |